Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients.
BACKGROUND
Renal-vein thrombosis (RVT) is an infrequent event that accounts for a high proportion of early renal allograft losses, since graft failure secondary to acute irreversible rejection is now relatively rare. The cause of RVT may be related to technical problems, clotting disorders, diabetes, or cyclosporin, but is often difficult to define.


METHODS
This retrospective study was performed to examine the influence of aspirin on the incidence of RVT in cadaveric and living-related renal transplant recipients receiving cyclosporin-based triple immunosuppression. The Oxford Transplant Centre database was used to identify all early (<30 day) non-immunological graft failures and case histories were examined for clinical and pathological evidence of RVT. In July 1991, aspirin (75 mg o.d. starting immediately before and continuing for 1 month post-transplant) was introduced as routine prophylaxis against RVT. Prior to this, aspirin prophylaxis was not used.


RESULTS
In the 6-year period from July 1985 to June 1991, there were 27 cases of RVT in 475 transplants (5.6%). In the subsequent 6-year period, there were six cases of RVT in 480 transplants (1.2%) (P:<0.01).


CONCLUSIONS
Although not abolished, this indicates a significant reduction in the incidence of RVT with the addition of low-dose aspirin.
Robertson
A J
AJ
Nuffield Department of Surgery, Oxford Transplant Centre, Churchill Hospital, Headington, Oxford, UK.
Nargund
V
V
Gray
D W
DW
Morris
P J
PJ
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D019992:Databases as Topic; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology; D019520:Living Donors; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011899:Ranitidine / Q000627:therapeutic use; D012082:Renal Veins; D012189:Retrospective Studies; D013997:Time Factors; D014019:Tissue Donors; D017211:Treatment Failure; D020246:Venous Thrombosis / Q000453:epidemiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011899:Ranitidine; D001241:Aspirin